| Active substance | Ravulizumab |
| Holder | Alexion Pharma Belgium |
| Status | Running |
| Indication | treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin 4 antibody-positive (AQP4 +) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 17/09/2024 |